Focusrite

Today we're having a look at a proper British small-cap that's been through the wringer: Focusrite plc, ticker TUNE, listed on AIM (London's small-cap growth market — think of it as the UK's answer to Nasdaq's smaller listings).

If you've ever plugged a microphone into a little silver-and-red box to record a podcast or a guitar riff, there's a decent chance it was one of Focusrites products.

This one's not a "buy now, thank me later" tip. It's a "keep it on the watchlist and let's talk about why" kind of stock.

The Top-Down Bit: Where Does This Sit?

Now, worth being a bit more precise than "just a microphone company" here, because it's not quite that simple anymore. Focusrite actually runs two divisions these days:

Content Creation — the bit most people know: Focusrite, Novation, ADAM Audio, Sequential and Oberheim, plus Sonnox software. This is your home-studio, podcaster, bedroom-producer kit.
Audio Reproduction — Martin Audio, Linea Research, Optimal Audio and a few others. This is professional live sound and installed audio — the speakers at gigs, festivals, and venues, not the box on your desk.

Audio Reproduction alone brought in roughly £46 million of the latest £164.6 million in revenue. So this isn't purely a "content creator" story anymore — a meaningful chunk of the business lives in live events and professional installs, which is a genuinely different demand cycle to home recording gear. Niche corner of the market either way, not a big flashy sector, so don't expect it topping any "hottest sector" lists.

What Actually Happened to This Company

Focusrite had an absolutely stellar pandemic. Everyone stuck at home decided to become a podcaster or a bedroom producer, demand went bananas, and the share price rocketed up towards £18 back in 2021. I myself love playing the guitar and have a Focusrite Scarlett on my desk so I can plug the guitar into my computer, a must have!

Reality turned up. People stopped buying new kit once they already had it, and then US tariffs threw a spanner in the works because a big chunk of their sales are American while a lot of the manufacturing happens in China. The share price fell off a cliff — from around £18 down towards roughly £1.30 at the low.

That's the "why is it so cheap" bit sorted. Now the "is it interesting again" bit.

The Fundamentals

Revenue: on a comparable 12-month basis to February 2026, revenue was £164.6 million, up 1.3% reported and 2.7% organically at constant currency. Modest, not spectacular — and it's worth knowing the company hasn't publicly promised specific growth numbers for the next couple of years, just that first-quarter trading was ahead of last year and full-year expectations are unchanged.
Debt: genuinely low and getting lower — net debt fell by £9.3 million to just £8.6 million, against £24.7 million of adjusted EBITDA. That's a company that isn't drowning in interest payments, which matters a lot for a swing trade — the last thing you want is a debt scare wiping out your setup.
Earnings — Adjusted diluted earnings per share actually fell 7.7%, from 16.9p to 15.6p, mainly down to higher finance charges and tax. Profit hasn't been growing steadily — the EBITDA and margin picture is improving, but that hasn't yet fully worked its way down to the bottom line. Worth being straight about that rather than glossing over it.
The statutory picture looks messier than it is: the group also posted a headline operating loss on a statutory basis, but that's almost entirely down to a £9.8 million non-cash write-down on the Sequential synthesiser brand (weak demand plus a factory relocation), not the core business turning loss-making. Strip that one-off out and adjusted operating profit was a healthy £15.1 million.
The multiple: at the current price of roughly 240p and last reported adjusted diluted EPS of 15.6p, the trailing P/E works out to around 15 times. You'll see lower figures (around 13x) floating about online — those are forward-looking estimates based on future broker forecasts, not what the shares are trading on today, so make sure you know which one you're looking at before comparing it to anything historical.

What the Chart's Actually Saying

The 52-week range is roughly 150p to 255p, and the shares have recovered strongly off that 150p low — they're now trading up near 240p, above the major longer-term moving averages rather than tangled up sideways.

So it's not really a flat, going-nowhere chart anymore. It's an emerging recovery that's now bumping up against resistance in the 255-260p zone — which happens to be the 52-week high. That's the level to watch.

For us trend traders, that's a useful level: a decisive close above 255-260p on strong volume would be proper technical confirmation that buyers are in control, not just a stock quietly drifting up off its lows.

Sentiment Check — Following the Crowd

This is a smaller, thinly-covered stock, so don't expect a big wave of City analysts all shouting about it at once. Current consensus shows around four covering analysts, all rated Buy or Outperform, with price targets ranging roughly 300p to 395p. That's genuinely positive — but with small-cap stocks like this, always check more than one source and check the date, since some of the online "consensus" numbers you'll find are frankly a bit dodgy and don't agree with each other. Trust the company's own trading updates over random aggregator websites every time.

Risk and Headspace Corner

A couple of things worth keeping in your back pocket with a name like this:

It's been burned before. Analysts have slashed their forecasts on this one in the past, hard. Don't fall in love with any single estimate.
Earnings haven't caught up with sentiment yet. EPS just fell year-on-year even while the share price has been climbing. That gap is worth watching — either earnings need to start delivering, or the market's getting ahead of itself.
Thin trading, thin coverage. Fewer eyes on it means moves can be sharper and gappier than a big FTSE 100 name.
Psychology bit: it's tempting to buy something because it "used to be worth loads more" — that's your brain doing bargain-hunting, not trend-following. Wait for the chart to confirm the story before your money goes anywhere near it. FOMO on a stock already near its 52-week high is how good traders turn into bagholders.

What Could Spark Some Growth

This is actually the more interesting bit of the Focusrite story and why it peaked my interest, because it's less about "will demand come back" and more about "are they trying to become a different, better business."

The company has spent roughly £6 million over four years building a new cross-brand technology platform, including its own proprietary silicon chip. The stated aims are faster product development, more reuse of shared technology across their different brands, better functionality, and improved supply-chain control and margins. The first product using this new platform is expected later in 2026, with more to follow over the next few years.

Worth being clear about what's confirmed and what's my own reading of it: everything above is what the company itself has said. What follows is my interpretation, not a management promise.

My take — this setup has echoes of what Apple did with its own chips plus tightly integrated software, which is part of what makes brand ecosystems sticky and hard to leave. If Focusrite's platform ends up doing something similar — locking customers into their ecosystem, maybe eventually supporting some kind of recurring software revenue — that would be a genuinely different, more valuable kind of business than "sell a box once every five years." But I want to be upfront: management hasn't said any of that. No subscription model has been announced. This is a plausible bull case built on the strategic logic, not a confirmed plan, so don't price it in as if it's already happening.

The Positives

The core financials are moving the right way. Revenue growing modestly, EBITDA up, gross margins up, debt falling fast — that's a business getting healthier, even before you get to the new platform story.
It builds a genuine moat, on paper. Hardware alone is easy to copy — plenty of rivals make decent audio interfaces. Hardware plus proprietary silicon plus shared software is much harder to replicate, if it works.
They're funding this sensibly. Not blowing the balance sheet apart — debt's low and falling, they're still cash generative, and the annual dividend increased slightly to 6.74p (though as of writing that final dividend still needs shareholder approval at the AGM, so it's not fully locked in yet).
Real analyst support, even if the coverage pool is small. Four analysts, all positive, targets well above the current price.

The Negatives

Earnings actually went backwards last year. Adjusted diluted EPS fell 7.7%. The recovery story is real at the EBITDA/margin level, but it hasn't reached the bottom line yet.
There's no proof of concept on the new platform yet. Again, nothing's launched. Everything said about ecosystem lock-in or stickier revenue (mine or anyone else's) is speculation until a product's actually out there and customers vote with their wallets.
Apple had billions and decades. Focusrite doesn't. This is a company worth around £140 million trying a strategy that took one of the richest companies on Earth the best part of 20 years and vast R&D budgets to pull off. Doesn't mean it can't work on a smaller scale in a niche market — but it's a harder road than the comparison makes it sound.
The old risks haven't fully gone away. Tariffs, US-China trade tension, and the general cyclicality of people not needing new kit every year are all still live, sitting alongside this new growth story rather than being cancelled out by it.
The Sequential brand is genuinely struggling. That £9.8 million impairment reflects real weak demand for high-end synths, not just an accounting technicality — worth watching whether management can turn that specific brand around or whether it keeps being a drag.

The Honest Take

This is a recovery story with a genuine growth angle layered on top, not a pure growth story yet. Revenue, margins and debt are all heading in the right direction; earnings per share isn't, at least not yet. The new technology platform is a credible, sensibly funded bet on a stickier future business — but it's still a bet, with the first real evidence due later this year.

So, Buy It or Not?

Still not a "buy now" call, and I'm not going to soften that just for a punchier ending. But the picture has moved on since the fundamentals were last cheap and the chart was going nowhere — the shares have already recovered a long way off their 150p low and are now sat right underneath the 255-260p resistance zone, which is also the 52-week high.

That's a genuinely different setup to "flat and forgotten." It means the next real test isn't years away — it's whether this thing can punch through that resistance on strong volume. If it does, you've got a name where the fundamentals (falling debt, improving margins, a funded growth platform) and the technicals (a confirmed breakout to new highs) are finally pointing the same way, which is exactly the combination we like round here.

Keep it on the list. Set an alert around 255-260p. Let the chart do the confirming, not the story.

Not financial advice — just a couple of blokes chatting about charts. Always do your own research and never risk more than you can afford to lose.